Ціна SuperRareRARE

According to recent news, the Major of Telegram team continues to optimize the functions of its NFT number rental platform to provide users with more convenient and diverse rental options. Since the platform launched two weeks ago, more than 888 NFT numbers have been rented through $MAJOR. Recent updates released by the team include:-Optimized design of the market page: Users can view the details of the required number at a glance on the market page, including the lease period, total cost and expiration date.-New rental sorting option: Provides rental users with a filtering function based on short-term or long-term rental preferences to improve market operation efficiency.-Add one month rental period: Provide users with more flexible options.In addition, the team has given away rare achievements to the first 100 Top Major users, and users can view relevant rewards through their personal profiles. At the same time, in order to promote the value of NFT achievements, the Major team plans to launch the function of upgrading achievements to NFT in early 2025 and develop a supporting pledge system. Users will be able to earn higher yields by staking rare achievements and significantly increase their token capital. It is worth noting that the user's NFT number can not only obtain a pledge return of up to 2.5% annualized return, but also obtain an annualized return of up to 26% after successful leasing. The current average selling price of NFT numbers on the platform is approximately $1,400. Officially, the Major team will continue to release more exciting updates in 2025, so stay tuned.

MTOS/USDT Remains Stable Amid Mixed Market Signals The $MTOS /USDT pair is holding steady at $0.009, reflecting no change in its price over the past 24 hours. With a 24-hour trading volume of 8 million MTOS and a turnover of $71.78K, the market activity for this token suggests a consolidation phase. The price action has seen a daily high of $0.010 and a low of $0.008, indicating minimal volatility compared to other cryptocurrencies. The token's 5-period moving average (MA) stands at 113.11K, while the 10-period MA is higher at 165.14K, hinting at a balanced market scenario. The 1-hour candlestick chart displays a period of sideways movement, which can often precede a breakout or breakdown. The lack of strong directional momentum could either signal trader indecision or reflect stability, a rare occurrence in the highly volatile crypto space. MTOS’s performance over the past week shows an impressive 125% growth, suggesting that it has recently experienced significant upward momentum. However, the current lack of movement may indicate that the market is pausing for consolidation. Investors should watch closely for volume changes or technical indicators that might suggest the next move.

MTOS/USDT Remains Stable Amid Mixed Market Signals The $MTOS /USDT pair is holding steady at $0.009, reflecting no change in its price over the past 24 hours. With a 24-hour trading volume of 8 million MTOS and a turnover of $71.78K, the market activity for this token suggests a consolidation phase. The price action has seen a daily high of $0.010 and a low of $0.008, indicating minimal volatility compared to other cryptocurrencies. The token's 5-period moving average (MA) stands at 113.11K, while the 10-period MA is higher at 165.14K, hinting at a balanced market scenario. The 1-hour candlestick chart displays a period of sideways movement, which can often precede a breakout or breakdown. The lack of strong directional momentum could either signal trader indecision or reflect stability, a rare occurrence in the highly volatile crypto space. MTOS’s performance over the past week shows an impressive 125% growth, suggesting that it has recently experienced significant upward momentum. However, the current lack of movement may indicate that the market is pausing for consolidation. Investors should watch closely for volume changes or technical indicators that might suggest the next move.

On Monday, Jones Trading initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) stock with a Buy rating and a price target of $130.00. The firm highlighted the biotech company's focus on RNA editing as a significant factor in its positive outlook. Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from Jones Trading expressed confidence in the potential of Korro Bio's technology, specifically the use of ADAR to modify proteins in vivo. This approach is expected to not only address AATD but also pave the way for treatments in more common conditions such as pain, liver disease, and cardiovascular disease. In anticipation of Korro Bio's progress, Jones Trading is looking forward to initial data from the Phase 1/2a study of KRRO-110, which is expected in the second half of 2025. The firm's optimism is also supported by Korro Bio's recent partnership with Novo Nordisk (NYSE:NVO) for cardiometabolic diseases, seeing this as an indicator of possible larger deals in the future due to the pharmaceutical industry's interest in RNA editing technologies. Jones Trading's initiation of coverage with a Buy rating and a $130 price target reflects a significant endorsement of Korro Bio's prospects in the biotechnology sector. The company's innovative approach to RNA editing positions it as a notable player in the development of treatments for a range of diseases. In other recent news, Korro Bio has seen significant advancements in RNA editing technology and strategic partnerships. RBC Capital Markets raised Korro Bio's stock price target to $105, following a positive outlook on RNA editing. The company's management expressed confidence in the potential of RNA editing after evaluating recent industry developments and data from peers.

On Monday, Jones Trading initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) stock with a Buy rating and a price target of $130.00. The firm highlighted the biotech company's focus on RNA editing as a significant factor in its positive outlook. Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from Jones Trading expressed confidence in the potential of Korro Bio's technology, specifically the use of ADAR to modify proteins in vivo. This approach is expected to not only address AATD but also pave the way for treatments in more common conditions such as pain, liver disease, and cardiovascular disease. In anticipation of Korro Bio's progress, Jones Trading is looking forward to initial data from the Phase 1/2a study of KRRO-110, which is expected in the second half of 2025. The firm's optimism is also supported by Korro Bio's recent partnership with Novo Nordisk (NYSE:NVO) for cardiometabolic diseases, seeing this as an indicator of possible larger deals in the future due to the pharmaceutical industry's interest in RNA editing technologies. Jones Trading's initiation of coverage with a Buy rating and a $130 price target reflects a significant endorsement of Korro Bio's prospects in the biotechnology sector. The company's innovative approach to RNA editing positions it as a notable player in the development of treatments for a range of diseases. In other recent news, Korro Bio has seen significant advancements in RNA editing technology and strategic partnerships. RBC Capital Markets raised Korro Bio's stock price target to $105, following a positive outlook on RNA editing. The company's management expressed confidence in the potential of RNA editing after evaluating recent industry developments and data from peers.